Clinical Trials Using PI3K-delta Inhibitor PWT143

Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K-delta Inhibitor PWT143. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

    A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
    Location: 12 locations

  • Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

    This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed / refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy
    Location: 7 locations

  • Zandelisib and R-CHOP for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

    This phase I / II trial studies the effects of zandelisib in combination with R-CHOP in treating patients with newly diagnosed diffuse large B-cell lymphoma. Zandelisib may suppress cancer growth by inhibiting, or blocking, a molecule called PI3K delta, which is typically present in normal lymphocytes and lymphoma cells. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone make up the R-CHOP regimen. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and vincristine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving zandelisib in combination with R-CHOP may help treat patients with newly diagnosed diffuse large B-cell lymphoma.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio